Small Health
AUSTIN, Texas, June 26, 2024 (GLOBE NEWSWIRE) — Tiny Health, offering the first at-home gut microbiome test for infants, and Rupa Health, a platform leader in specialty clinical testing, with a shared mission to transform preventive care, address the root causes of health issues and improve health outcomes for future generations, have announced a collaboration to expand access to comprehensive at-home microbiome testing to Rupa's vast network of healthcare providers.
“We are facing a childhood chronic disease crisis, with nearly 1 in 2 children living with at least one chronic condition. We know that by identifying and correcting microbiome imbalances during the first 1,000 days of life, a critical period of immune development, families can avoid or reverse these diseases,” said Cheryl Sew Hoy, CEO of Tiny Health. “We're excited to partner with Rupa Health to support healthcare professionals in their efforts to provide better preventative care.”
With this partnership, Tiny Health's Gut Health Test, PRO Gut Health Test and Vaginal Test are now available to Rupa's extensive network of healthcare providers across the U.S., joining the 800+ healthcare providers already using Tiny Health for their clients and patients. The move further accelerates the growth of Powered by Tiny, Tiny Health's B2B arm, a platform that scales microbiome-based solutions through clinical trials, healthcare provider and research partnerships and co-branded gut and vaginal testing kits.
Tiny Health Gut Microbiome Test
Rupa Health is an innovator in transparency for clinical testing. The Rupa platform brings together 30+ clinical testing companies and 3,000+ tests into a single interface for healthcare professionals to order, manage, track and get results, while creating a modern and seamless digital experience for patients.
“We are strong advocates of root-cause medicine, and there is growing evidence showing the role the gut microbiome plays in shaping overall health. Offering Tiny Health's innovative microbiome testing on the Rupa platform will advance preventative care and early intervention,” said Tara Viswanathan, CEO and co-founder of Rupa. “We are excited to work with Tiny Health to strengthen our network and serve healthcare providers and patients at every stage of life.”
Tiny Health is the most comprehensive at-home gut and vaginal microbiome test for families. Their test leverages the power of deep shotgun metagenomic sequencing to identify over 120,000 bacteria, viruses, fungi and protozoan parasites down to 0.05% relative abundance. It also includes probiotic strain tracking, age-specific insights into disease condition associations, and the potential to reveal microbiome risk for chronic diseases like eczema and allergies.
The story continues
“Through this partnership, healthcare professionals and the families they serve can access the latest microbiome science now and take action when they need it most, not 10 years from now,” said Seow Hui.
About Tiny Health:
Founded in 2020, Tiny Health helps families take control of their gut health to improve long-term health outcomes. Built by a team of microbiome scientists and early childhood experts, our innovative tests educate consumers about their body's microbes and provide evidence-based interventions to optimize overall health. Serving more than 25,000 families across the U.S., Tiny Health offers gut health testing at every stage of life, from the womb through adulthood. To learn more about Tiny Health, visit tinyhealth.com. Practitioners and businesses can explore partnership opportunities at PoweredbyTiny.com.
About Rupa Health
Rupa Health helps healthcare professionals order, track and manage 3,000+ test results from 30+ lab companies in one interface. It also offers training for healthcare professionals through educational bootcamps and free live classes through RupaUniversity.com. Healthcare professionals can sign up for free and start ordering by visiting RupaHealth.com.
Media Contact
Small Health
inquiry
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4e78c174-dee4-4f98-8b4f-1f5591e8b647
